Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00064103
Status:
COMPLETED
Last Update Posted:
2013-01-23
First Post:
2003-07-08
Brief Title:
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector NCI Supplied Agent Ad-p53 INGN 201 Advexin NSC 683550 IND 7135
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase III trial is studying the side effects and best dose of gene therapy and to see how well it works in preventing cancer in patients with premalignant carcinoma of the oral cavity or pharynx Inserting the p53 gene into a persons tumor cells may improve the bodys ability to kill the tumor cells
Detailed Description:
OBJECTIVES
I Determine the acute toxic effects of Ad5CMV-p53 gene administered as an oral rinse and as an intramucosal injection in patients with diffuse premalignant carcinoma of the oral cavity or oral pharynx
II Determine the maximum tolerated dose of this drug in these patients III Determine the topical transduction efficiency of adenoviral-mediated wild type p53 gene transfer in patients treated with this drug
IV Determine the efficacy of this drug in reversing the histology of oral premalignancies in these patients
V Determine the distribution of transgenic protein within the area of the premalignant lesion in patients treated with this drug
OUTLINE This is an open-label dose-escalation study of Ad5CMV-p53 gene administered as an oral rinse
Phase I Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1 Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5 Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
Phase II Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD Patients are followed every 3 months for 1 year every 6 months for 1 year and then annually for 3 years Patients then receive long-term follow-up annually for an additional 10 years
I Determine the acute toxic effects of Ad5CMV-p53 gene administered as an oral rinse and as an intramucosal injection in patients with diffuse premalignant carcinoma of the oral cavity or oral pharynx
II Determine the maximum tolerated dose of this drug in these patients III Determine the topical transduction efficiency of adenoviral-mediated wild type p53 gene transfer in patients treated with this drug
IV Determine the efficacy of this drug in reversing the histology of oral premalignancies in these patients
V Determine the distribution of transgenic protein within the area of the premalignant lesion in patients treated with this drug
OUTLINE This is an open-label dose-escalation study of Ad5CMV-p53 gene administered as an oral rinse
Phase I Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1 Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5 Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
Phase II Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD Patients are followed every 3 months for 1 year every 6 months for 1 year and then annually for 3 years Patients then receive long-term follow-up annually for an additional 10 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MDA-ID-00193 | None | None | None |
| P50CA097007 | NIH | None | None |
| CDR0000306522 | REGISTRY | PDQ Physician Data Query | httpsreporternihgovquickSearchP50CA097007 |